Epitalon vs Humanin: A Tetrapeptide and a 24-Mer Compared

Put Epitalon and humanin next to each other in a search result and they look like neighbors. Both turn up in longevity-adjacent peptide research. Both get described as cellular-aging compounds. Both are sold as research-grade material for research use only — not for human or animal consumption. The resemblance stops there. Epitalon is four amino acids long; humanin is 24. That six-fold gap in chain length isn't trivia. It decides what shape each molecule can hold, which decides what it can bind, which decides what a study can even be designed to test. Below: both sequences, where each one came from, and what the published cell-culture record actually reports.

Side by Side on Paper

The short answer first — these are not analogs of each other. Different sizes, different biological sources, different structural logic.

The AEDG tetrapeptide

Epitalon is a tetrapeptide consisting of Ala-Glu-Asp-Gly (AEDG) bound through α-peptide bonds. Alanine, glutamic acid, aspartic acid, glycine, in that order, and nothing else. The chain carries three asymmetric centers, which in principle permits eight stereoisomers, though the form that appears throughout the research literature is built exclusively from L-amino acids. It's a strongly hydrophilic molecule, and commercial research material usually arrives either as the free base or as an acetate or trifluoroacetate salt.

The 24-residue humanin chain

Humanin runs six times longer: MAPRGFSCLLLLTSEIDLPVKRRA, molecular formula C₁₁₉H₂₀₄N₃₄O₃₂S₂, molar mass roughly 2,687 g/mol. There's a wrinkle in that residue count. Researchers report either a 21- or 24-amino-acid polypeptide depending on whether translation occurs in mitochondria or cytoplasm, and papers describing the mitochondrial variant sometimes list only the first 20 residues of the same sequence. Both lengths are described as biologically active. The ambiguity isn't sloppiness — it reflects a real open question about where in the cell the peptide gets made.

Two Very Different Origin Stories

Where a peptide comes from tells you what it was doing before anyone synthesized it. These two histories barely touch.

Epitalon from pineal extract chemistry

Epitalon wasn't discovered as a free peptide at all. It was synthesized based on the amino acid composition of Epithalamin, a bovine pineal gland extract — meaning the sequence was reverse-engineered from what the extract was made of. Its presence in the human body then stayed unconfirmed for decades. The review authors note it was detected in physiological pineal gland extract for the first time only in 2017. Keep that gap in mind when reading the older literature, because much of it studies a synthetic compound whose endogenous counterpart hadn't yet been shown to exist.

Humanin from a mitochondrial open reading frame

Humanin arrived by a completely different route. Researchers identified it in 2001 using a modified "death-trap" screening, in the unaffected occipital brain of a patient with sporadic Alzheimer's disease. The surprise was the source: this peptide is encoded inside mitochondrial DNA, in a small open reading frame that overlaps the 16S ribosomal RNA coding region of the MT-RNR2 gene.

That genomic address puts humanin in a named structural class. Mitochondrial-derived peptides, or MDPs, originate from unconventional open reading frames within rRNA genes rather than dedicated protein-coding sequences. Alongside humanin sit the small humanin-like peptides (SHLPs, 24 to 38 residues, also from 16S rRNA) and MOTS-c (16 residues, from 12S rRNA). For the closer sibling comparison, we covered how humanin compares with MOTS-c separately. Epitalon belongs to no such family. There's no genomic reading frame behind it.

One more origin-side finding is what gave humanin its foothold in aging research: circulating levels of humanin decrease with age in both human and mice, and in mouse models those levels track inversely with growth-hormone signaling — elevated in long-lived GH-deficient Ames mice, lower in short-lived GH-transgenic mice.

What Four Residues Can and Cannot Do

If you take one thing from this comparison, take this: the structural difference between these peptides follows almost directly from their length.

Secondary structure needs a longer chain

Humanin is long enough to fold. Published structural work describes beta-sheet domains at residues 6–14 and an alpha-helix at residues 19–24, plus a poly-leucine motif spanning residues 9–12. Those are recognizable secondary-structure elements — the same vocabulary used for proteins, just on a much smaller canvas.

What holds a four-residue chain together instead

Four residues can't form a beta sheet or a helix. There isn't enough chain to work with. What molecular dynamics studies on Epitalon describe instead is a different stabilizing trick: the peptide forms two intramolecular salt bridges which stabilize its structure, between alanine's nitrogen and the carboxylic groups of the glutamic and aspartic acid residues. The result isn't a fold. It's a constraint — a short chain pinned into a narrow set of conformations rather than one adopting a defined architecture.

Short is not the same as weak

Reading "four residues" as "less potent" would be a mistake. Very short peptides routinely carry real activity through mechanisms longer chains never need — GHK-Cu, a tripeptide whose whole function rests on coordination chemistry, is the clearest case. And inside a single peptide family, even a one-residue difference can change how a peptide behaves. Short chains trade folding capacity for a different mode of action, not for irrelevance.

Where Each Peptide Makes Contact

The two compounds have been studied binding entirely different classes of molecular partner — and that divergence is downstream of the structure.

Humanin: mapped protein and receptor interactions

Because humanin has enough surface area to work with, researchers have been able to assign specific functions to specific residues. The structural review identifies a BAX binding site at residue 8, an IGFBP3 binding region spanning residues 6–21, and a self-dimerization domain at residue 7. Functionally, the peptide binds Bcl2-associated X protein (BAX), Bim and tBid, and IGFBP3 to inhibit caspase activity and cell apoptosis inside the cell. Once secreted, it engages cell-surface machinery instead: the G-protein-coupled formyl peptide receptor-like 1 (FPRL1/2), plus a CNTFR-α/gp130/WSX-1 trimeric receptor complex that drives JAK2/STAT3 signaling.

Epitalon: nucleic acid motifs and histones

Epitalon's reported partners aren't proteins at the cell surface. The review literature describes sequence-selective interaction with the DNA motifs ATTTC and CAG through hydrogen bonds and hydrophobic contacts. A separate line of work pushes further and proposes that direct DNA binding isn't the main event at all: those authors hypothesize that the AEDG peptide most preferably binds to histones H1/6 and H1/3 at sites that interact with DNA, competing with the histones for those contact points and so shifting the probability that nearby genes get transcribed. Whether that model holds up remains open. But it's a fundamentally different mechanism from receptor engagement.

What the Cell-Culture Record Actually Shows

Here's what has been observed, in which model systems, at what concentrations — stated as laboratory observations, not as outcomes anyone should expect.

Epitalon and telomere length

A 2025 study tested the peptide across normal and cancer human cell lines and found two different routes to the same endpoint. In normal IBR.3 fibroblasts and HMEC epithelial cells exposed for three weeks at 1.0 µg/mL, epitalon can extend telomere length in normal healthy mammalian cells through the upregulation of hTERT mRNA expression and telomerase enzyme activity. The cancer lines behaved differently. In 21NT and BT474 cells exposed for four days at 0.1–1.0 µg/mL, hTERT expression rose but telomerase enzyme activity did not increase significantly; instead, alternative lengthening of telomeres (ALT) activity went up roughly tenfold in 21NT and threefold in BT474. The authors note that ALT was not activated in the normal lines. An earlier report cited in the Epitalon review described average telomere elongation of about 33.3% in human lymphocytes.

Epitalon and gene expression in stem cells

In human gingival mesenchymal stem cells exposed to AEDG peptide in concentration 0.01 µg/mL for 1 week, mRNA for four neurogenic markers rose modestly: β-tubulin III by 1.8-fold, nestin by 1.7-fold, doublecortin by 1.7-fold, GAP43 by 1.6-fold. Related work in human periodontal ligament stem cells reported statistically significant elevation of GAP43 and nestin transcription.

Humanin in cytoprotection models

Humanin's cell-culture literature centers on mitochondrial and apoptotic endpoints rather than telomeres. Across MDP studies, humanin exposure has been reported to rescue mitochondrial structure and function and restore mitochondrial membrane potential, alongside lower intracellular reactive oxygen species in amyloid-β-exposed cells.

Why a 24-Mer Gives Chemists More to Work With

A longer sequence is a longer list of positions you can change one at a time, and humanin's analog catalog shows what that buys. The HNG variant carries a single serine-to-glycine substitution at position 14 and is reported as up to 1000x more potent depending on the assay. HNGF6A swaps phenylalanine for alanine at position 6. Truncated fragments HN(1-19) and HN(1-17) retain activity at reduced potency — which itself helps map where the active region sits.

Epitalon's four positions leave almost no room for that kind of structure-activity mapping. Change one residue and you've altered a quarter of the molecule. That constraint is part of why its structure-activity literature stays thin.

Reading the Evidence Base Critically

Both literatures come with limitations the authors state themselves, and those caveats are the most useful thing a reader can carry away.

The telomere study is explicit about its own ceiling: it was an in vitro study using human cell lines in 2D cell cultures, and the researchers recommend 3D cultures and animal models for more physiologically relevant results. The Epitalon review is equally candid — despite a publication record spanning more than 25 years, the authors write that the quantity of physico-chemical and structural investigations of this peptide remains quite limited. On the humanin side, the translation site is still incompletely understood, which is exactly why the 21-versus-24-residue question hasn't closed. If you want a sense of what fully resolving a peptide structure actually takes, our explainer on how researchers resolve peptide structures in solution covers the methods.

The Bottom Line

Epitalon and humanin aren't two versions of the same idea. Four residues versus 24 is a gap wide enough to put them in separate categories of molecule: one a synthetic tetrapeptide reverse-engineered from a gland extract and studied mostly through nucleic acid and chromatin interactions, the other a genomically encoded 24-mer with mapped receptor complexes and a family of engineered analogs. Neither is an FDA-approved pharmaceutical, and research-grade material is not equivalent to any approved product. Read as a pair, though, they make a useful lesson in how to approach peptide research generally: check the length, check the origin, check the model system, and check what the authors say they could not conclude.

Frequently Asked Questions

Is Epitalon the same kind of molecule as humanin?

No. Both are peptides, and that is close to where the similarity ends. Epitalon is a synthetic four-residue sequence, Ala-Glu-Asp-Gly, modeled on the amino acid composition of a pineal gland extract. Humanin is a 24-residue peptide encoded inside the mitochondrial genome, in an open reading frame overlapping the 16S ribosomal RNA gene. They differ in length, origin, structure, and in the molecules each has been shown to interact with.

How long is each peptide, exactly?

Epitalon is four amino acids: alanine, glutamic acid, aspartic acid, glycine — written AEDG. Humanin in its cytosolic form is 24 amino acids, MAPRGFSCLLLLTSEIDLPVKRRA, with a molecular formula of C₁₁₉H₂₀₄N₃₄O₃₂S₂ and a molar mass near 2,687 g/mol. A shorter form produced inside the mitochondrion is reported at 21 residues.

Why does chain length matter for a peptide?

Length determines what shapes a chain can hold. Humanin is long enough to fold into recognizable secondary structure — a beta-sheet region across residues 6–14 and an alpha-helix across residues 19–24. Four residues cannot do that; molecular dynamics work on Epitalon instead describes two intramolecular salt bridges locking the short chain into a constrained shape. Length also sets how much surface is available for protein binding, which is why humanin has several mapped binding regions and Epitalon does not.

Does one of these peptides have more research behind it?

They have different kinds of research behind them. Epitalon has a publication record stretching back more than 25 years, largely from one research tradition, and a 2025 review notes that physico-chemical and structural investigation of the peptide remains quite limited relative to that volume. Humanin has a shorter history, dating to its 2001 identification, but sits inside a broader and more structurally characterized field — the mitochondrial-derived peptides.

Are either of these compounds approved for human use?

No. Neither Epitalon nor humanin is an FDA-approved pharmaceutical product. Research-grade material sold for laboratory work is not equivalent to an approved drug of any name, and the findings described here come from cell-culture and animal-model studies rather than established clinical practice. Material of this kind is for research use only and is not for human or animal consumption.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.